Cyclooxygenase involvement in thromboxane-dependent contraction in rat mesenteric resistance arteries

Hypertension

Volumn 43, Issue 6, 2004, Pages 1264-1269

  Bolla, Manlio ^a   You, Dong ^b   Loufrani, Laurent ^b   Levy, Bernard I ^b   Levy Toledano, Sylviane ^a   Habib, Aïda ^a   Henrion, Daniel ^a,b  

^a INSERM   (France)

^b Unit 541   (France)

Author keywords

Cyclooxygenase; Prostaglandins; Resistance; Thromboxane

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ENDOPEROXIDE; FLURBIPROFEN; FUREGRELATE; INDOMETACIN; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SC 58560; THROMBOXANE; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTERIOGRAPHY; ARTERY BLOOD FLOW; ARTERY CONSTRICTION; ARTERY DIAMETER; ARTERY PERFUSION; ARTERY RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME IMMUNOASSAY; ENZYME INHIBITION; ENZYME RELEASE; HYPERTENSION; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROST; DINOPROSTONE; ENDOTHELIN-1; FLURBIPROFEN; HYDRAZINES; INDOMETHACIN; ISOENZYMES; MALE; MEMBRANE PROTEINS; MESENTERIC ARTERIES; ORGANIC CHEMICALS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RATS; RATS, INBRED WKY; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; SULFONAMIDES; THROMBOXANE A2; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 2542562737     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000127438.39744.07     Document Type: Article

References (28)

1. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79:1193-1226.
2. Noll G, Luscher TF. The endothelium in acute coronary syndromes. Eur Heart J. 1998;19:C30-C38.
3. Cediel E, Vazquez-Cruz B, Navarro-Cid J, De Las Heras N, Sanz-Rosa D, Cachofeiro V, Lahera V. Role of endothelin-1 and thromboxane A2 in renal vasoconstriction induced by angiotensin II in diabetes and hypertension. Kidney Int Suppl. 2002;82:2-7.
4. Paarlberg KM, de Jong CL, van Geön HP, van Kamp GJ, Heinen AG, Dekker GA. Vasoactive mediators in pregnancy-induced hypertensive disorders: a longitudinal study. Am J Obstet Gynecol. 1998;179:1559-1564.
5. Matrougui K, Maclouf J, Lévy BI, Henrion D. Impaired nitric oxide- and prostaglandin-mediated responses to flow in resistance arteries of Hypertensive rats. Hypertension. 1997;30:942-947.
6. Ungvafi Z, Koller A. Endothelin and prostaglandin H(2)/thromboxane A(2) enhance myogenic constriction in hypertension by increasing Ca(2+) sensitivity of arteriolar smooth muscle. Hypertension. 2000;36:856-861.
7. Habib A, Vezza R, Créminon C, Maclouf J, FitzGerald GA. Rapid, agonist-dependent phosphorylation in vivo of human thromboxane receptor isoforms. J Biol Chem. 1997;272:7191-7200.
8. Ge T, Hughes H, Junquero DC, Wu KK, Vanhoutte PM, Boulanger CM. Endothelium-dependent contractions are associated with both augmented expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin H2 in the SHR aorta. Circ Res. 1995;76:1003-1010.
9. Reilly M, FitzGerald GA. Cellular activation by thromboxane A2 and other eicosanoids. Eur Heart J. 1993;14:88-93.
10. FitzGerald GA, Austin S, Egan K, Cheng Y, Pratico D. Cyclo-oxygenase products and atherothrombosis. Ann Med. 2000;32:21-26.
11. Bishop-Bailey D, Hla T, Mitchell JA. Cyclo-oxygenase-2 in vascular smooth muscle. Int J Mol Med. 1999;3:41-48.
12. Davis MJ, Hill MA. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev. 1999;79:387-423.
13. Christensen KL, Mulvany MJ. Location of resistance arteries. J Vasc Res. 2001;38:1-12.
14. Shimokawa H. Endothelial dysfunction in hypertension. J Atheroscler Thromb. 1998;4:118-127.
15. Silldorff EP, Hilbun LR, Pallone TL. Angiotensin II constriction of rat vasa recta is partially thromboxane dependent. Hypertension. 2002;40:541-546.
16. White LR, Juul R, Cappelen J, Aasly J. Cyclooxygenase inhibitors attenuate endothelin ET(B) receptor-mediated contraction in human temporal artery. Eur J Pharmacol. 2002;12:448:51-57.
17. Bolla M, Matrougui K, Maclouf J, Loufrani L, Levy BI, Levy-Toledano S, Habib A, Henrion D. p38 MAP kinase activation is required for thromboxane induced contraction in perfused and pressurized rat mesenteric resistance arteries. J Vasc Res. 2002;39:353-360.
18. Halpern W, Kelley M. In vitro methodology for resistance arteries. Blood Vessels. 1991;28:245-251.
19. Vila JM, Medina P, Segarra G, Aldasoro M, Noguera I, Lluch S. Endothelin-1-induced potentiation of adrenergic responses in the rabbit pulmonary artery: role of thromboxane A(2). Eur J Pharmacol. 2001;413:247-254.
20. Wang JL, Cheng HF, Zhang MZ, McKanna JA, Harris RC. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol. 1998;275:F613-F622.
21. Walch L, de Montpreville V, Brink C, Norel X. Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Br J Pharmacol. 2001;134:1671-1678.
22. Peredo HA. Defibrotide modulates prostaglandin production in the rat mesenteric vascular bed. Prostaglandins Leukot Essent Fatty Acids. 2002;67:211-216.
23. Henrion D, Chillon JM, Capdeville-Atkinson C, Vinceneux-Feugier M, Atkinson J. Chronic treatment with the angiotensin I converting enzyme inhibitor, perindopril, protects in vitro carbachol-induced vasorelaxation in a rat model of vascular calcium overload. Br J Pharmacol. 1991;104:966-972.
24. Malik KU, Ryan P, McGiff JC. Modification by prostaglandins E1 and E2, indomethacin, and arachidonic acid of the vasoconstrictor responses of the isolated perfused rabbit and rat mesenteric arteries to adrenergic stimuli. Circ Res. 1976;39:163-168.
25. Ren J, Karpinski E, Benishin CG. Prostaglandin E2 contracts vascular smooth muscle and inhibits potassium currents in vascular smooth muscle cells of rat tail artery. J Pharmacol Exp Ther. 1995;275:710-719.
26. Rapoport RM, Williams SP. Role of prostaglandins in acetylcholine-induced contraction of aorta from spontaneously hypertensive and Wistar-Kyoto rats. Hypertension. 1996;28:64-75.
27. Pratico D, Cheng Y, FitzGerald GA. TP or not TP: primary mediators in a close runoff? Arterioscler Thromb Vasc Biol. 2000;20:1695-1698.
28. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:1724-1728.